83397-45-9

Basic information

• Product Name: Benzeneaceticacid, a,a-dimethyl-4-nitro-, ethyl ester
• Synonyms: Ethyl2-(4-nitrophenyl)-2-methylpropanoate; Ethyl2-methyl-2-(4-nitrophenyl)propionate
• CAS NO: 83397-45-9
• Molecular Formula: C12H15 N O4
• Molecular Weight: 237.255
• Mol File: 83397-45-9.mol
• Article Data: 33

Chemical Properties

• CAS DataBase Reference: Benzeneaceticacid, a,a-dimethyl-4-nitro-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneaceticacid, a,a-dimethyl-4-nitro-, ethyl ester(83397-45-9)
• EPA Substance Registry System: Benzeneaceticacid, a,a-dimethyl-4-nitro-, ethyl ester(83397-45-9)

Safety Data

• Hazardous Substances Data: 83397-45-9(Hazardous Substances Data)

Upstream product

• 5445-26-1 ETHYL 4-NITROPHENYLACETATE 
• 865-48-5 sodium t-butanolate 
• 74-88-4 methyl iodide 
• 7664-93-9 sulfuric acid 
• 71825-51-9 4-(2-cyanoprop-2-yl)-1-nitrobenzene 
• 50712-64-6 ethyl 2-(4-nitrophenyl)propionate 
• 7646-69-7 sodium hydride 
• 1195-98-8 2-methyl-2-phenylpropionitrile 
• 2901-13-5 ethyl 2-methyl-2-phenylpropionate 
• 98-95-3 nitrobenzene 
• 535-13-7 2-chloro-propanoic acid, ethyl ester 

Downstream Products

• 18755-53-8 2-methyl-2-(4-nitrophenyl)propan-1-ol 
• 18755-56-1 2-(4-aminophenyl)-2-methylpropan-1-ol 
• 192643-90-6 ethyl 2-(4-hydrazinophenyl)-2-methylpropanoate 
• 1076219-29-8 2-[2-(3,5-dimethylphenyl)-1H-indol-5-yl]-(N-cyclopropyl)-2-methylpropanamide 
• 1076220-87-5 2-[2-(3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropanoic acid 
• 1076219-12-9 ethyl 2-methyl-2-{2-[4-(trifluoromethoxy)phenyl]-1H-indol-5-yl}propanoate 
• 1076219-11-8 ethyl 2-[2-(3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropanoate 
• 357193-21-6 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-{[(2,4-dinitrophenyl)sulfonyl]amino}-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-23-8 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-1-methyl-2-[(2-pyridin-4-ylethyl)amino]ethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-15-8 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-(benzyloxy)-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-17-0 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-azido-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-19-2 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-amino-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-16-9 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-hydroxy-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-14-7 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-(benzyloxy)-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole 

Relevant articles and documents

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound shown as a formula I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Experiments prove that the compound has good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor and drugs for preventing and/or treating IL-17A mediated diseases (such as inflammation, autoimmune diseases, infectious diseases, cancers and precancerous syndromes), and provides a new medical possibility for clinical treatment of diseases related to abnormal IL-17A activity.

COMPOUNDS AND METHODS FOR INHIBITING CYP26 ENZYMES

Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.